Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT04592237
Title	Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer
Recruitment	Recruiting
Gender	male
Phase	Phase II
Variant Requirements	Yes
Sponsors	M.D. Anderson Cancer Center
Indications	prostate small cell carcinoma prostate carcinoma
Therapies	Niraparib Cabazitaxel + Carboplatin + Cetrelimab Cetrelimab + Niraparib
Age Groups:	adult \| senior
Covered Countries	USA